AZD 6553Alternative Names: AZD6553
Latest Information Update: 06 Oct 2010
At a glance
- Originator AstraZeneca
- Mechanism of Action Leucocyte elastase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 22 Sep 2010 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (PO)
- 29 Jul 2010 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO)